SPOP: new treatment target for renal cancer

In recent years, the incidence of renal cancer increased the rate of malignant tumors in the first place. Clinical treatment shows that renal cancer is not sensitive to radiotherapy and chemotherapy. VEGFR inhibitors such as sorafenib and sunitinib are the first-line drugs for advanced renal cell carcinoma. Although FDA-approved drugs for kidney cancer treatment has been up to ten, these drugs are very limited efficacy of metastatic renal cell carcinoma, and susceptible to drug resistance. According to previous research using recombinant mouse proteins, it is a very important and urgent task to discover and confirm the new drug targets for the treatment of RCC-specifics.

Liu Jiang, a researcher at the Beijing Genomics Institute of the Chinese Academy of Sciences, discovered early that the SPP of the ubiquitin ligase E3 family member Cul3-binding substrate protein was overexpressed in 99% of clear-cell renal cell carcinoma tissues and was expressed in normal renal tissue SPOP and is still a biomarker of clear cell renal cell carcinoma. SPOP is still overexpressed in metastatic clear cell renal carcinoma. Liu Jiang group further study showed that SPOP is incorrectly positioned in the cytoplasm cell renal cell carcinoma. Overexpression of hypoxia-inducible factor HIF transcription enhances SPOP overexpression and hypoxic microenvironment drives the accumulation of overexpressed SPOP proteins in the cytoplasm of renal carcinoma and ultimately promotes the formation of renal carcinoma.

The above fundamental research in biology poses a key scientific question whether small molecule compounds can targetly interfere with SPOP-mediated protein interactions to achieve specific treatment of clear cell renal cell carcinoma. In order to study the interaction between SPOP and protein, SPROP was used to identify the crystal structure of the substrate polypeptide complex, and the structure-based screening strategy was used in combination with drug Chemical synthesis optimization and other technical means. The successful acquisition of SPOP can be combined with small molecule compounds. The compound can inhibit the binding of SPOP to substrate protein, interfering with the SPOP-mediated regulation of ubiquitination of PTEN, DUSP7 and other ubiquitination-modified signal transduction pathway, and ultimately inhibiting the growth of clear cell renal carcinoma cells in vitro and in vivo. This important result is published in the journal Cancer Cell. This study provides evidence for the pharmacological function of SPOP as a target for clear-cell renal cell carcinoma, as well as a new direction for the discovery of SPOP inhibitors and for the treatment of renal cell carcinoma, unlike kinase inhibitors. Almost at the same time, Nature has published two reports on the hypoxia-inducible factor HIF-2α inhibitor PT2399 (analogue PT2385 has entered the clinical stage), suggesting that the HIF pathway for the Small molecule inhibitors will also become a new target for renal cancer treatment. Flarebio offers recombinant proteins of good quality such as recombinant Itgb2 for your research.

Scientists have new breakthrough in motor proteins

Researchers at Penn State suggest that motor proteins which pause at the ends of microtubules and produce pushing forces can also stimulate their growth. The function of the proteins is a critical component in understanding cell division and nerve branching and growth, according to research using recombinant horse proteins.

Kinesins are found in multicellular organisms. They are a family of motor proteins. They act as little engines within the cells and transport molecular cargo along microtubules. The microtubules are hollow cylinders of the protein tubulin. They are dynamic and can grow and shrink when the cell change shape.

The researchers are trying to understand more about the motor and what makes the sequences unique since they carry out so many vital functions in the cells.

There are forty-five different kinesin motor proteins in human body in all. The researchers tracked the movements of each one and found that motor pauses at the end of the microtubules. Later it produces pushing forces to slide the microtubules apart and allow the motor to grow the microtubules. Their findings are reported in Nature Communications recently.

They bound microtubules to a microscope slide and added free tubulin subunits together with modified kinesin-5 motor proteins. The results showed that the motor proteins added improve the rate and persistence of microtubule growth.

In conclusion, if we can terminate cancer cell division, new approaches in treatment will come into being. Therefore, understanding more about how kinesin-5 influences microtubule dynamics and its importance in properly segregating genetic material in cell division is of great concern. Flarebio provides you with recombinant proteins of good quality including recombinant Dpp4.

To locate and surveil immune cell of human body with new technology

The immunotherapy of using human immune cells to attack cancer cells is the current international scientific research focus, but how immune cells specifically functions in vivo has always been a mystery. US researchers have recently developed a new method for the first time through recombinant rat proteins to achieve location and surveillance of immune cell of human body.

At this stage, immunotherapy still has its limitations. The effect of immune cells finding and killing cancer cells is sometimes better than conventional cancer therapy, but sometimes does not work. Doctors often have to wait a few months to check whether the tumor shrinks to know whether the immune cells attack cancer cells. If immunotherapy does not work, then the cancer cells may have spread or become more difficult to deal with.

Researchers at Stanford University and other researchers in the United States reported online on the academic journal Science Translational Medicine that they have spent 10 years and have found a way to track immune cells.

They have genetically engineered immune cells from patients and added a "reporter gene", a gene that directs the synthesis of a protein that can be detected by positron emission tomography. After the genetically-modified immune cells being injected back to the human body, by detecting the relevant protein, we can know the location of immune cells, the number of information, and we can analyse whether they are close to the tumor and attack.

The researchers successfully tested this technique in glioblastoma patients. They say that new technologies can also be used to track immune cells against other cancers. "The technique, which can show how the living body's immune system works without removing any human tissue, is unprecedented," says research director, Professor Sanjee Gambier from Stanford University. Flarebio offers superior recombinant proteins such as recombinant Dpp4 at good prices.

A new leap forward the prevention and treatment of fatty liver treatment

Researchers from the Institute of Biomedical Sciences (Barcelona Biomedical Research Institute) and IDIBAPS Biomedical Research Institute published their research using recombinant mouse proteins in the journal Nature Cell Biology. The researchers hope that this discovery will lead to a new leap forward the prevention and treatment of fatty liver treatment. One of the co-leaders of the study, IDIBAPS group leader Dr. Mercedes Fernández, said that it laid a good foundation for subsequent applied sciences.

Fatty liver is caused by depletion of CPEB4 in mice, and no one knows exactly what causes fatty liver, although we do know that people who are obese or overweight, or those with diabetes, high cholesterol or high triglycerides are more likely to suffer from fatty liver. In addition, rapid weight loss and poor eating habits can also lead to fatty liver. However, NAFLD may also occur in some populations without these risk factors.

Dr. Fernández and his colleagues noted that some large genomics studies have found that gene variants that encode CPEB4 are associated with dyslipidemia. In their study, the murine liver of CPEB4 was lowly expressed in the study. They found that with age, mice gradually developed fatty liver. They also found that feeding a high-fat diet to young mice deficient in CPEB4 resulted in a more pronounced fatty liver.

Further studies on the expression of CPEB4 at the molecular level suggest that this protein plays a key role in the liver stress response. For example, placing a liver cell in a stressful state caused by a high-fat diet can disturb the balance of a cell component called endoplasmic reticulum (ER). When lacking for CPEB4, ER shows less response on the stress. ER has many functions, including the production of protein and lipid and the removal of excess waste.

The researchers found that ER regains its balance by releasing CPEB4 to adapt to stress - for example, removing excess waste. They also found that circadian rhythms affected the release of CPEB4; it was more active during the day (the liver had a lot of work to do) and was quietest at night. The team believes that without CPEB4, ER can not fully restore the balance of stress, which will lead to fat accumulation, forming fatty liver. Flarebio offers high-quality recombinant proteins like recombinant TLR2 for your research.

To study protein dynamics in a new way

Researchers have developed the first computational method based on evolutionary principles to predict protein dynamics. These researchers are from the Structural Biology Computational Group of the Spanish National Cancer Research Centre (CNIO), led by Alfonso Valencia, together with a group led by Francesco Gervasio at the University College London (UK). Protein dynamics can explain the changes in the shape or dimensional structure that they experience in order to interact with other compounds or speed up chemical reactions. This study push the development of the computational study of protein dynamics, and it is helpful for the design of drugs and for the research about genetic disease. It is published in the journal Proceedings of the National Academy of Sciences (PNAS), which also publishes other studies on recombinant dog proteins.

As we know, proteins are crucial to the thousands of cellular functions which work in a living organism. It is chains of smaller molecules which are called amino acids that form the protein - a three-dimensional structure. By studying the co-evolution of amino acids, we can reconstruct the form or structure of these biological compounds in their natural surroundings. We can also predict physical contacts between amino acids with higher accuracy and in sufficient number by analyzing the sequences of a given family of proteins, to reconstruct the folding and structure of a protein accurately.

Nevertheless, the structure won't remain changeless. It interacts with other biological compounds or with drugs, which is called protein dynamics. The study about it turns out to be extremely difficult no matter through experimental observations or computational tools.

"We developed a model in which the amino acids that have a strong co-evolutionary relationship attracted each other, without further additional data," says Simone Marsili, researcher who has also participated in the project. "First, we simulate the folding process and then we can see how the simulations were able to predict the changes in shape of the proteins at different levels of complexity, including those required for kinases to function." Flarebio offers superior recombinant proteins like recombinant TLR2 at competitive prices.

Scientists are trying to push Porcn inhibitor as a regenerative agent for heart disease

Anticancer agents which are under development can promote the regeneration of damaged myocardium , and they may help to prevent congestive heart failure in the future. The results of the study have been published in the Proceedings of the National Academy of Sciences, which also publishes other studies on recombinant human proteins.

Dr. Lawrence Lum, associate professor of cell biology at UT Southwestern Medical Center, has been developing cancer drugs for Wnt signaling molecules for many years. These molecules are essential for tissue regeneration, but also often lead to cancer. What's crucially important for the production of the human Wnt protein is the porcupine (Porcn) enzyme, because Drosophila embryo lacking this gene is similar to Porcn. They were curious when testing Porcn inhibitors developed by the researchers.

"We saw a lot of predictable adverse effects in bone and hair, but one unexpected result was a slight increase in the number of split myocytes (cardiomyocytes)," said senior author Dr Lum. "In addition to a strong interest in Porcn inhibitors in anticancer agents, this study suggests that this agent can be used in regenerative medicine."

Based on their preliminary results, the researchers induced heart attacks in mice and then treated with Porcn inhibitors. Compared with untreated animals, their blood pumping capacity of the heart increased nearly twice. Dr. Rhonda Bassel-Duby, director of the Center for Regenerative Sciences and Medicine, professor of molecular biology and molecular biology, said, "Our laboratory has been studying cardiac repair for a few years. Surprisingly, the administration of Wnt inhibitors significantly improved mice Cardiac function after a heart attack."

Importantly, in addition to improving pumping capacity in mouse hearts, the researchers also noted a reduction in cardiac fibrosis or scarring. Collagen load scars that occur after a heart attack can lead to an undue increase in the size of the heart and lead to heart failure. "Although fibrotic reactions may be immediately beneficial, they may overwhelm the ability of the heart to regenerate over a long period of time, and we believe that we have a drug that can modulate this fibrosis response, thereby improving wound healing in the heart," said Dr. Murchison Linthicum, Harold C. Simmons Comprehensive Cancer Center, deputy director of basic research and a medical researcher.

In addition, Professor Lum said preliminary experiments showed that Porcn inhibitors only need to be used within a short time after a heart attack, suggesting that the unpleasant side effects which are usually caused by cancer drugs can be avoided. "We hope to push the Porcn inhibitor into clinical trials within the next year as a regenerative agent for heart disease," Dr. Lum said. Flarebio provides you with high-quality recombinant proteins including recombinant ITGB5.

To find a new and effective anticancer drug target

Cancer is a heterogeneous disease, and signaling pathways plays an important role in the occurrence and progress of cancer. According to research through recombinant horse proteins, different gene mutations can cause different signal pathway abnormalities, resulting in the performance of different clinical subtypes. Different subtypes of various anti-cancer drug reactivity will be quite different. Complex signaling pathways affect the survival of cancer patients rate and prognosis. It is a difficult problem to find a new and effective anticancer drug target to regulate the corresponding signal pathway.

Ras gene is a kind of oncogene, including K-ras, H-ras and N-ras. They can promote cell proliferation and growth in normal cells. When it shows mutation activation, Ras signaling pathway promotes cell proliferation and then malignant transformation of cells happens. In February, the electronic edition of Cell published an article by Tim wang from the University of Cambridge, Massachusetts. Under the mentoring guidance of Whitehead Institute and the Cambridge broad Institute, the researchers conducted gene sequencing on 14 acute lymphatic Cell leukemia patients and compared the main gene map and the known genomic data and found that the genotype of cancer patients will be divided into different subtypes, contributing to the development of new treatment and application.

This article tittled Major Gene Analysis Reveals the Roles of Oncogene Ras and Lethal Interactions in Gene Network Synthesis focuses on the role of genes and proteins in Ras signaling pathways in the treatment of acute lymphoblastic leukemia and other malignant diseases. The study found that, once Ras protein occurs, the disease will develop and drug therapy can be said to have been "powerless". Only from the gene level inhibition of Ras signaling pathway can effectively prevent the occurrence of malignant tumors.

With the development of genetic engineering technology, by knocking out 18,000 protein-coding genes one by one in the human genome through CRISPR-based gene editing technology, we can find the regulatory role of the Ras signaling pathway genes so as to find new anti-cancer gene target and to promote individualized treatment of cancer. It is believed that in the near future, the target drug acting on the Ras signal pathway can be applied to the clinical treatment of malignant diseases. Flarebio offers suprior recombinant proteins such as recombinant ITGB5 at good prices.